Lyra Therapeutics Analyst Ratings
Lyra Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/06/2023 | 291.64% | BTIG | → $15 | Assumes | → Buy |
| 10/02/2023 | 213.32% | HC Wainwright & Co. | → $12 | Reiterates | Buy → Buy |
| 09/12/2023 | 291.64% | B of A Securities | $13 → $15 | Maintains | Buy |
| 08/31/2023 | 213.32% | HC Wainwright & Co. | → $12 | Initiates Coverage On | → Buy |
| 02/07/2023 | 422.19% | BTIG | $24 → $20 | Maintains | Buy |
| 05/24/2022 | 291.64% | Cantor Fitzgerald | → $15 | Initiates Coverage On | → Overweight |
| 05/26/2020 | 448.3% | B of A Securities | → $21 | Initiates Coverage On | → Buy |
| 05/26/2020 | 526.63% | Jefferies | → $24 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 10/06/2023 | 291.64% | BTIG | →$15 | 假设 | →购买 |
| 10/02/2023 | 213.32% | HC Wainwright公司 | →$12 | 重申 | 购买→购买 |
| 09/12/2023 | 291.64% | B of A证券 | $13→$15 | 维护 | 买 |
| 2023年08月31日 | 213.32% | HC Wainwright公司 | →$12 | 开始承保 | →购买 |
| 02/07/2023 | 422.19% | BTIG | $24→$20 | 维护 | 买 |
| 2022年05月24日 | 291.64% | 康托·菲茨杰拉德 | →$15 | 开始承保 | →超重 |
| 05/26/2020 | 448.3% | B of A证券 | →$21 | 开始承保 | →购买 |
| 05/26/2020 | 526.63% | 杰富瑞 | →$24 | 开始承保 | →购买 |
What is the target price for Lyra Therapeutics (LYRA)?
Lyra治疗公司(Lyra)的目标价格是多少？
The latest price target for Lyra Therapeutics (NASDAQ: LYRA) was reported by BTIG on October 6, 2023. The analyst firm set a price target for $15.00 expecting LYRA to rise to within 12 months (a possible 291.64% upside). 5 analyst firms have reported ratings in the last year.
莱拉治疗公司(纳斯达克：莱拉)的最新目标价是由BTIG于2023年10月6日报道的。这家分析公司将目标价定为15美元，预计Lyra将在12个月内上涨至(可能上涨291.64)。去年有5家分析公司公布了评级。
What is the most recent analyst rating for Lyra Therapeutics (LYRA)?
天琴座治疗公司(Lyra)的最新分析师评级是多少？
The latest analyst rating for Lyra Therapeutics (NASDAQ: LYRA) was provided by BTIG, and Lyra Therapeutics their buy rating.
莱拉治疗公司(纳斯达克：莱拉)的最新分析师评级是由北大西洋投资集团提供的，莱拉治疗公司的最新评级为买入。
When is the next analyst rating going to be posted or updated for Lyra Therapeutics (LYRA)?
Lyra治疗公司(Lyra)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lyra Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lyra Therapeutics was filed on October 6, 2023 so you should expect the next rating to be made available sometime around October 6, 2024.
分析师在进行了广泛的研究后得出股票评级，其中包括查阅公共财务报表，与Lyra治疗公司的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Lyra治疗公司的上一次评级是在2023年10月6日提交的，所以你应该预计下一次评级将在2024年10月6日左右的某个时候提供。
Is the Analyst Rating Lyra Therapeutics (LYRA) correct?
分析师对Lyra Treateutics(Lyra)的评级正确吗？
While ratings are subjective and will change, the latest Lyra Therapeutics (LYRA) rating was a with a price target of $0.00 to $15.00. The current price Lyra Therapeutics (LYRA) is trading at is $3.83, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Lyra治疗公司(Lyra)评级为A，目标价在0.00美元至15.00美元之间。Lyra治疗公司(Lyra)目前的交易价格为3.83美元，在分析师的预测范围内。